SO019RENAL AUTONOMIC NERVES ARE RESPONSIBLE FOR BODY WEIGHT REDUCTION BY TOFOGLIFLOZIN [PDF]
Nephrology Dialysis Transplantation, 2016 openaire +1 more source
Tofogliflozin, a SGLT2 inhibitor, improves diabetic ocular complications in Spontaneously Diabetic Torii rats [PDF]
Diabetes Updates, 2019 Toyoda F +9 more
openaire +1 more source
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. [PDF]
HepatologyQi X, Li J, Caussy C, Teng GJ, Loomba R.
europepmc +1 more source
Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential. [PDF]
MoleculesZieliński M +3 more
europepmc +1 more source
Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. [PDF]
Front Med (Lausanne)Yang L, Ruan J, Fang Y, Xu A.
europepmc +1 more source
Effect of Baseline Values of Renal Prognosis-related Factors on Their Changes after Initiating Tofogliflozin Treatment: A Retrospective Study in Japanese Patients with Type 2 Diabetes and Renal Impairment. [PDF]
JMA JMatsumoto S +8 more
europepmc +1 more source
SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. [PDF]
Endocrinol Metab (Seoul)Noh SW, Ryu HS, Kim YH, Oh BC.
europepmc +1 more source
SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]
J Diabetes ResAlfonso Arvez MJ +4 more
europepmc +1 more source
Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment? [PDF]
PharmaceuticsKaufmann D, Schlesinger N.
europepmc +1 more source